🧾 What This Document Is

This is an 8-K filing, a report companies submit to the SEC to announce major, shareholder-impacting news. In this case, Stoke Therapeutics is formally announcing the appointment of a new expert, Clare Kahn, Ph.D., to its Board of Directors. It’s a standard but important update for investors to see who is steering the ship.

🏢 What The Company Does

👉 In simple terms, Stoke is a biotech company trying to fix diseases caused by a missing copy of a critical gene. They use custom-designed medicines (called antisense oligonucleotides or ASOs) to tell the body's cells to make more of the needed protein from the one good gene copy they have left. Their main focus is on serious diseases of the brain and eye.

🚀 The Key Move: A New Board Member

The core of this filing is the appointment of Dr. Clare Kahn to the Board.

• Her Background: She brings over 30 years of experience in drug development and regulatory strategy, with past senior roles at Pfizer and GlaxoSmithKline. Most recently, she was an executive at a biotech called X-VAX.
• Why She's Important: CEO Ian F. Smith highlights her expertise in rare genetic diseases is crucial right now. Stoke is advancing its lead drug through a final Phase 3 study, and her guidance on navigating the complex path to drug approval will be vital.

💊 The Disease: Dravet Syndrome

Stoke’s work centers on Dravet syndrome, a severe form of childhood epilepsy.

• The Cause: It’s usually caused by a mutation in one copy of the SCN1A gene, leading to a shortage of a key brain protein called NaV1.1.
• The Reality: Patients suffer from frequent seizures and serious developmental challenges. Current anti-seizure drugs often don’t work well, and tragically, up to 20% of children do not survive to adulthood. It affects an estimated ~16,000 people in the U.S. and up to 38,000 in major global markets. There are no approved treatments that modify the disease itself.

💊 The Drug: Zorevunersen

Stoke’s promising investigational medicine is called zorevunersen.

• How It Works: It’s an ASO designed to boost protein production from the one healthy copy of the SCN1A gene, aiming to treat the root cause, not just symptoms.
• Fast-Tracked Status: The FDA has granted it Orphan Drug Designation (for rare diseases), Rare Pediatric Disease Designation, and the highly sought-after Breakthrough Therapy Designation, which signals potential for substantial improvement over existing treatments.
• A Major Partnership: Stoke has a key collaboration with Biogen to develop and commercialize this drug. Stoke keeps rights in North America, while Biogen handles the rest of the world.

📅 What's Next

The immediate focus is clear: advance the Phase 3 clinical study of zorevunersen. With Dr. Kahn's board-level expertise now on board, the company is reinforcing its leadership team for this critical late-stage development period and the work toward potential future drug approval and commercialization.

⚖️ Big Picture

👍 Strengths: Adding a board member with deep regulatory and rare disease experience is a strategic move for a company in late-stage trials. The drug has Breakthrough Therapy Designation, and they have a deep-pocketed partner in Biogen. ⚠️ Risks: Clinical trials can always fail, and the path to approval is never guaranteed. The disease area, while high-need, is also highly complex. The company's success is heavily tied to the outcome of the ongoing zorevunersen study.

🧠 The Analogy

Stoke is like a team of construction engineers trying to fix a critical power outage in a city (Dravet syndrome). One power plant (the good gene copy) is working, but it’s not producing enough electricity (protein). Their tool, zorevunersen, is like a smart upgrade to make that one plant work harder. Bringing in Dr. Kahn is like hiring a veteran city planner who knows every regulation and shortcut to get the new power system approved and connected to the grid as quickly and safely as possible.

🧩 Final Takeaway

This appointment is a strategic reinforcement of Stoke Therapeutics' leadership as it heads into the make-or-break Phase 3 trial for its lead drug, zorevunersen. It signals to investors that the company is arming itself with expert guidance for the tough regulatory and development road ahead.